Form 8-K

8-K — Journey Medical Corp

Accession: 0001104659-26-046158

Filed: 2026-04-21

Period: 2026-04-21

CIK: 0001867066

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2612310d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2612310d1_ex99-1.htm)

GRAPHIC (tm2612310d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2612310d1_8k.htm · Sequence: 1

false

0001867066

2026-04-21

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event

reported): April 21, 2026

Journey Medical Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware

001-41063

47-1879539

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(I.R.S.

Employer

Identification No.)

9237 E Via de Ventura Blvd., Suite 105

Scottsdale, AZ 8525

(Address of principal executive offices)

Registrant’s telephone number, including

area code: (480) 434-6670

Check the appropriate box below if the Form

8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered

pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange

on which registered

Common Stock

DERM

The Nasdaq Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01

Other Events.

On April 21, 2026, Journey

Medical Corporation (the “Company”) announced an expansion in pharmacy benefit coverage for Emrosi™ (40 mg Minocycline

Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release), the Company’s treatment for the inflammatory

lesions of rosacea in adults. A copy of the press release issued by the Company is attached hereto as Exhibit 99.1 and incorporated herein

by reference.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are furnished herewith:

Exhibit

Number

Description

99.1

Press release issued by Journey Medical Corporation, dated April 21, 2026

104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Journey Medical Corporation

(Registrant)

By:

/s/ Claude Maraoui

Claude Maraoui

Chief Executive Officer, President and Director

Date: April 21, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2612310d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Journey Medical

Corporation Secures Contract with Third Major GPO for Emrosi™

Payer access for Emrosi™ expanded from

approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026

Scottsdale, AZ – April 21, 2026 –

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”),

a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing FDA-approved prescription pharmaceutical

products for the treatment of dermatological conditions, today announced that approximately

85% of all commercial lives in the United States now have access to Emrosi™ (40

mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) after

contracting with the third major group purchasing organization (GPO). Emrosi™ is

for the treatment of inflammatory lesions of rosacea in adults. Journey Medical

continues to execute on the launch of Emrosi™, with expanded payer

access anticipated to facilitate further growth in total prescription demand.

“We are extremely pleased with the completion

of this milestone for Emrosi™,” said Claude Maraoui, Co-Founder, President, and CEO of Journey Medical Corporation. “Our

focus on delivering cost-effective access to high-quality dermatology therapies is expected to expand coverage and improve patient access,

positioning Emrosi™ for sustained commercial growth. Now that our contracts have been secured with the three major GPOs, we look

forward to continuing to increase coverage for Emrosi™ for patients nationwide by converting access into coverage. Our efforts remain

on health plan formulary adoption, on both a national and regional level, throughout 2026 and beyond, supporting Emrosi’s™

potential to become the standard of care in rosacea and driving long-term value creation. As formulary adoption continues to increase,

we expect there to be less reliance on our co-pay bridging program and an improvement in profitability for the brand.”

About Rosacea

Rosacea is a chronic, relapsing, inflammatory

skin condition that most commonly presents with symptoms such as deep facial redness, acne-like inflammatory lesions (papules and pustules)

and spider veins (telangiectasia). According to The National Rosacea Society, it is estimated that rosacea affects

over 17 million Americans and as many as 415 million people worldwide. Rosacea is most frequently seen in adults between 30 and

50 years of age. Surveys conducted by The National Rosacea Society report that more than 90 percent of rosacea patients

said their condition had lowered their self-confidence and self-esteem, and 41 percent stated that it had caused them to avoid public

contact or cancel social engagements. Among rosacea patients with severe symptoms, 88 percent said the disorder had adversely affected

their professional interactions, and 51 percent said they had missed work because of their condition.

Important Safety Information

Indication: EMROSI™ is indicated

for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. Adverse Events: The most common

adverse reaction reported by ≥1% of subjects treated with EMROSI and more frequently than in subjects receiving placebo was dyspepsia. Contraindications: EMROSI

should not be taken by patients who have a history of hypersensitivity to any of the tetracyclines. Warnings/Precautions: Cases

of anaphylaxis, serious skin reactions (e.g., Stevens-Johnson syndrome), erythema multiforme, and drug rash with eosinophilia and systemic

symptoms (DRESS) syndrome have been reported postmarketing with minocycline use in patients with acne. If DRESS syndrome is recognized,

discontinue EMROSI immediately. Use during the second and third trimesters of pregnancy, infancy and childhood up to the age of 8 years

may cause permanent discoloration of the teeth and reversible inhibition of bone growth. Discontinue EMROSI use if Antibiotic-Associated

Colitis occurs. Discontinue EMROSI if liver injury is suspected. Patients experiencing light-headedness, dizziness or vertigo should

be cautioned about driving vehicles or operating heavy machinery. Clinical manifestations include headache, blurred vision, diplopia,

and vision loss. Discontinue EMROSI immediately if symptoms occur. Symptoms may be manifested by fever, rash, arthralgia, and malaise.

Discontinue EMROSI immediately if symptoms occur. Patients should minimize or avoid exposure to natural or artificial sunlight while

using EMROSI. Tetracycline-class antibiotics are known to cause hyperpigmentation. EMROSI may induce hyperpigmentation in many organs,

including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity, sclerae and heart valves. Because of the potential for drug-resistant

bacteria to develop during the use of EMROSI, use EMROSI only as indicated. If superinfection occurs, discontinue EMROSI and institute

appropriate therapy. Perform periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic studies. You

are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or

call 1-800-FDA-1088.

For full prescribing information, please visit www.emrosi.com.

About Journey Medical Corporation

Journey Medical Corporation (Nasdaq: DERM) (“Journey

Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved

prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model.

The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey

Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most

successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq:

FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic

reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit

www.journeymedicalcorp.com.

Forward-Looking Statements

This press release may contain “forward-looking

statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange

Act of 1934, as amended. As used below and throughout this press release, the words “the Company”, “we”, “us”

and “our” may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth

strategy and product development programs and any other statements that are not historical facts. The words “anticipate,”

“believe,” “continue,” “estimate,” “may,” “expect,” “will,” “could,”

“project,” “intend,” “potential” and similar expressions are generally intended to identify forward-looking

statements. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties

that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results

to differ materially from those currently anticipated include: the fact that our products and future product candidates are subject to

time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial

portion of our sales derive from products that may become subject to third-party generic competition because their period of exclusivity

has ended or they are without patent protection, subjecting them to the potential introduction of new competitor products and/or an increase

in market share of existing competitor products, either of which could have a significant adverse impact on our operating income; we operate

in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may

have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of

such products could impair our operating results; competition could limit our products’ commercial opportunity and profitability,

including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance,

including by government and third-party payors; our reliance on third parties for several aspects of our operations; our dependence on

our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful;

the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful

commercialization of EmrosiTM and any future product candidates that we may develop, in-license or acquire; clinical drug development

is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of

our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks

related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology

and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our

or our third parties’ cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major

public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional

capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other

risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2025,

subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release

publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any

changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the

protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contact:

Jaclyn Jaffe

(781) 652-4500

ir@jmcderm.com

Media Relations Contact:

Tony Plohoros

6 Degrees

(908) 591-2839

tplohoros@6degreespr.com

GRAPHIC

Filename: tm2612310d1_ex99-1img001.jpg · Sequence: 6

Binary file (14135 bytes)

Download tm2612310d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 21, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 21, 2026

Entity File Number

001-41063

Entity Registrant Name

Journey Medical Corporation

Entity Central Index Key

0001867066

Entity Tax Identification Number

47-1879539

Entity Incorporation, State or Country Code

Entity Address, Address Line One

9237 E Via de Ventura Blvd.

Entity Address, Address Line Two

Suite 105

Entity Address, City or Town

Scottsdale

Entity Address, State or Province

Entity Address, Postal Zip Code

8525

City Area Code

480

Local Phone Number

434-6670

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

DERM

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration